November 21st 2024
The FDA granted an accelerated approval to zanidatamab-hrii for previously treated, unresectable or metastatic HER2-positve biliary tract cancer.
PER LIVER CANCER TUMOR BOARD: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable ...
November 16, 2024
Register Now!
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hematology Meeting: Preceding the 66th ASH Annual Meeting and Exposition
December 6, 2024
Register Now!
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
18th Annual New York GU Cancers Congress™
March 28-29, 2025
Register Now!
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®
View More
BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
Community Practice Connections™: 14th Asia-Pacific Primary Liver Cancer Expert Meeting
View More
Symptom Burden Higher in Newly Diagnosed Patients Reporting Financial Strain
March 25th 2016A study published by researchers at the Dana Farber-Cancer Institute recently discovered that financial status plays a large role in the level of symptom burden and quality of life for patients newly diagnosed with lung or colorectal cancer.
Racial Disparities Persist in Breast Cancer for Women and Colorectal Cancer in Men
March 1st 2016Racial disparities in mortality for breast cancer have gotten worse in women and persisted for colorectal cancer in men, although progress has been made in closing the mortality gap between blacks and whites for other cancers.
Danielle Novetsky Friedman on Abdominal Radiation and Diabetes Risk
February 1st 2016Danielle Novetsky Friedman, a general pediatrician in the Pediatric Long-Term Follow-Up Program at Memorial Sloan Kettering Cancer Center (MSK), discusses a study investigating the mechanisms leading to abnormal glucose and insulin dynamics in survivors of childhood cancers.
Robin Brenner on Side Effects of Onivyde for Pancreatic Cancer
January 29th 2016Robin B. Brenner, RN, CRN, OCN, clinical research nurse, David M. Rubinstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, discusses adverse events associated with Onivyde (irinotecan liposome injection; MM-398) for pancreatic cancer.
Michael Soulen on Radioembolization of Neuroendocrine Tumor Liver Metastases
December 10th 2015Michael Soulen, MD, a professor of radiology and surgery at the Abramson Cancer Center, University of Pennsylvania, discusses radioembolization to treat liver metastases in patients with neuroendocrine tumors (NETs) as well as the efficacy of embolization in treating NETs.
Information Empowers Patients With GI Malignancies
December 9th 2015Entering through the giant, inflatable colon, dozens of patients, caregivers, family members and providers gathered at the Georgetown University Hotel and Conference Center in Washington, DC, December 5 for the symposium, “Fighting a Smarter War Against Cancer.â€
Avoidable Colorectal Cancer Deaths Hit Low Socioeconomic Areas Hardest
December 4th 2015Disparities in colorectal cancer deaths have had a significant impact on the national economy, with areas of low socioeconomic status experiencing the greatest losses, according to a study by researchers at the Centers for Disease Control and Prevention (CDC).
Onivyde FDA Approved to Treat Metastatic Pancreatic Cancer
October 22nd 2015The FDA has approved MM-398, branded as Onivyde (irinotecan liposome injection) in combination with 5-fluorouracil (5-FU) chemotherapy and leucovorin for patients with metastatic pancreatic cancer. The treatment follows prior administration of a gemcitabine-based regimen.
"Hotspots" Highlight Need for Targeted Efforts to Promote Colorectal Cancer Screening
July 8th 2015Researchers have identified three "hotspots" in the United States where progress on reducing death rates from colorectal cancer have lagged, shining a light on areas of the country where efforts to increase screening uptake and promote healthier lifestyles could make a big difference.
Susan Mazanec on Activation for Health Management
April 28th 2015Susan R. Mazanec, PhD, RN, AOCN, Research Assistant Professor, Frances Payne Bolton School of Nursing, Case Western Reserve University, discusses a study that examined activation for health management in colorectal cancer patients and their family caregivers during the transition to post-treatment survivorship.
What Is Lynch Syndrome and Why Is It Important?
April 28th 2015Lynch syndrome (LS) is a hereditary syndrome that causes a marked increased risk of colorectal and other cancers. It is inherited in an autosomal dominant pattern, which means that it is due to a mutation in one copy of a gene (in LS, a DNA mismatch repair gene).
"Welcome to the Walk-through Colon" and Other GI Navigation Success Stories
April 27th 2015Oncology nurse navigators are known for identifying gaps in cancer care, being proactive in setting goals to address them, and designing specific interventions that lead not only to better-and measurable-outcomes but also to increased patient satisfaction.